BRCA1-associated growth arrest is RB-dependent
AUTOR(ES)
Aprelikova, Olga N.
FONTE
The National Academy of Sciences
RESUMO
BRCA1 is a susceptibility gene for breast and ovarian cancer with growth-inhibitory activity for which the mechanism of action remains unclear. When introduced into cells, BRCA1 inhibits growth of some but not all cell lines. In an attempt to uncover the mechanism of growth suppression by BRCA1, we examined a panel of cell lines for their ability to reduce colony outgrowth in response to BRCA1 overexpression. Of all variables tested, only those cells with wild-type pRb were sensitive to BRCA1-induced growth suppression. In cells with an intact rb gene, inactivation of pRb by HPV E7 abrogates the growth arrest imposed by BRCA1. In accordance with these observations, we found that BRCA1 could not suppress BrdUrd uptake in primary fibroblasts from rb−/− mice and exhibited an intermediate ability to inhibit DNA synthesis in rb+/− as compared with rb+/+ cells. We further found that the BRCA1 protein complexes with the hypophosphorylated form of pRb. This binding is localized to amino acids 304–394 of BRCA1 protein and requires the ABC domain of pRb. In-frame deletion of BRCA1 fragment involved in interaction with pRb completely abolished the growth-suppressive property of BRCA1. Although it has been reported that BRCA1 interacts with p53, we find the p53 status did not affect the ability of BRCA1 to suppress colony formation. Our data suggest that the growth suppressor function of BRCA1 depends, at least in part, on Rb.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=18378Documentos Relacionados
- RB-Dependent S-Phase Response to DNA Damage
- Preclinical mouse models for BRCA1-associated breast cancer
- The BRCA1-associated protein BACH1 is a DNA helicase targeted by clinically relevant inactivating mutations
- Vimentin and laminin expression is associated with basal‐like phenotype in both sporadic and BRCA1‐associated breast carcinomas
- Integrin β3 Leu33Pro polymorphism increases BRCA1‐associated ovarian cancer risk